A recently published seroprevalence study confirmed that the presence of COVID-19 antibodies renders protection against subsequent SARS-CoV-2 infections. Individuals above the age of 12 inclusive of seniors and comorbid participants with and without COVID-19 infections participated in the studies. Serological assays which included commercially available ELISA (Euroimmun, Lübeck, Germany #EI 2606-9601 G) and recombinant immunofluorescence assay (rIFA) were carried out in both seropositive and seronegative participants to detect the presence of specific antibodies against SARS-CoV-2 spike proteins. Seropositive participants are those who were infected since the onset of the disease (February 2020) and had SARS-CoV-2 antibodies.
After serological assays, the participants were followed up for a period of 35.6 and 34.7 weeks in seropositive and seronegative groups, respectively with a standard deviation of 3.2. Any infection among the participants was analyzed using RT-PCR. The outcomes obtained concluded that seropositive individuals were 94% less likely to be reinfected with SARS-CoV-2. Alternatively, the rate of confirmed SARS-CoV-2 infections was significantly higher in seronegative individuals. 1.4% of the seropositive population confirmed subsequent reinfection with the SARS-CoV-2 virus, whereas 15.5% of the seronegative participants contracted the virus. Seroconversion after both symptomatic and asymptomatic infections gave protection for up to eight months. This information can be useful for planning vaccination regimes if there is a scarcity of vaccines.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here